Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 5
1989 5
1991 2
1992 2
1993 2
1994 1
1995 1
1996 3
1997 5
1998 4
1999 3
2000 2
2001 1
2002 2
2003 3
2004 7
2005 4
2006 2
2007 5
2008 3
2009 4
2011 2
2015 1
2016 3
2017 2
2018 4
2019 4
2020 3
2021 3
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for B. kaisha
Your search for B. Kanisha retrieved no results
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U. Nowakowski GS, et al. J Clin Oncol. 2021 Apr 20;39(12):1317-1328. doi: 10.1200/JCO.20.01366. Epub 2021 Feb 23. J Clin Oncol. 2021. PMID: 33621109 Free PMC article. Clinical Trial.
PURPOSE: Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). ...
PURPOSE: Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed in …
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Nastoupil LJ, Hess G, Pavlovsky MA, Danielewicz I, Freeman J, García-Sancho AM, Glazunova V, Grigg A, Hou JZ, Janssens A, Kim SJ, Masliak Z, McKay P, Merli F, Munakata W, Nagai H, Özcan M, Preis M, Wang T, Rowe M, Tamegnon M, Qin R, Henninger T, Curtis M, Caces DB, Thieblemont C, Salles G. Nastoupil LJ, et al. Blood Adv. 2023 Nov 28;7(22):7141-7150. doi: 10.1182/bloodadvances.2023010298. Blood Adv. 2023. PMID: 37722354 Free PMC article. Clinical Trial.
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
Makita S, Maruyama D, Tobinai K. Makita S, et al. Onco Targets Ther. 2020 Jun 23;13:5993-6009. doi: 10.2147/OTT.S193951. eCollection 2020. Onco Targets Ther. 2020. PMID: 32606807 Free PMC article. Review.
Classical Hodgkin lymphoma (cHL) is a B-cell-derived lymphoid malignancy with the most favorable prognosis among various adult malignancies. ...
Classical Hodgkin lymphoma (cHL) is a B-cell-derived lymphoid malignancy with the most favorable prognosis among various adult malign …
Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A.
Kinoshita T, Watanabe T, Itoh K, Yoshimura K, Tobinai K, Ogura M, Yamaguchi M, Kurosawa M, Imaizumi Y, Ota S, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Tsukasaki K, Nagai H, Shimoyama M. Kinoshita T, et al. J Clin Exp Hematop. 2021;61(1):35-41. doi: 10.3960/jslrt.20062. J Clin Exp Hematop. 2021. PMID: 33731548 Free PMC article.
The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituxim …
The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by …
Cloning and nucleotide sequence analysis of gyrB of Bacillus cereus, B. thuringiensis, B. mycoides, and B. anthracis and their application to the detection of B. cereus in rice.
Yamada S, Ohashi E, Agata N, Venkateswaran K. Yamada S, et al. Appl Environ Microbiol. 1999 Apr;65(4):1483-90. doi: 10.1128/AEM.65.4.1483-1490.1999. Appl Environ Microbiol. 1999. PMID: 10103241 Free PMC article.
Oligonucleotide PCR primer sets were designed from within gyrB sequences of the respective bacteria for the specific amplification and differentiation of B. cereus, B. thuringiensis, and B. anthracis. The results from the amplification of gyrB sequences corre …
Oligonucleotide PCR primer sets were designed from within gyrB sequences of the respective bacteria for the specific amplification and diffe …
Pyrindamycins A and B, new antitumor antibiotics.
Ohba K, Watabe H, Sasaki T, Takeuchi Y, Kodama Y, Nakazawa T, Yamamoto H, Shomura T, Sezaki M, Kondo S. Ohba K, et al. J Antibiot (Tokyo). 1988 Oct;41(10):1515-9. doi: 10.7164/antibiotics.41.1515. J Antibiot (Tokyo). 1988. PMID: 3192502 Free article. No abstract available.
Biosynthesis of benanomicins.
Gomi S, Sezaki M, Hamada M, Kondo S, Takeuchi T. Gomi S, et al. J Antibiot (Tokyo). 1989 Jul;42(7):1145-50. doi: 10.7164/antibiotics.42.1145. J Antibiot (Tokyo). 1989. PMID: 2753819 Free article.
The biosynthesis of benanomicins A and B, produced by actinomycete strain MH193-16F4, was investigated by feeding experiments with 14C- and 13C-labeled compounds followed by measurement of radioactivity and 13C NMR analysis. ...
The biosynthesis of benanomicins A and B, produced by actinomycete strain MH193-16F4, was investigated by feeding experiments with 14 …
Application of superb micro-vascular imaging (SMI) in obstetrics.
Hasegawa J, Yamada H, Kawasaki E, Matsumoto T, Takahashi S, Suzuki N. Hasegawa J, et al. J Matern Fetal Neonatal Med. 2018 Jan;31(2):261-263. doi: 10.1080/14767058.2016.1278206. Epub 2017 Jan 23. J Matern Fetal Neonatal Med. 2018. PMID: 28111994
R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, Shimada K, Minauchi K, Fukuhara N, Kobayashi H, Yamauchi N, Tsujimura H, Hangaishi A, Tominaga R, Suehiro Y, Yoshida S, Inoue Y, Suzuki S, Tokuhira M, Kusumoto S, Kuroda J, Yakushijin Y, Takamatsu Y, Kubota Y, Nosaka K, Morishima S, Nakamura S, Ogura M, Maruyama D, Hotta T, Morishima Y, Tsukasaki K, Nagai H. Kagami Y, et al. Cancer Sci. 2020 Oct;111(10):3770-3779. doi: 10.1111/cas.14604. Epub 2020 Sep 11. Cancer Sci. 2020. PMID: 32767806 Free PMC article. Clinical Trial.
Overall survival at 2 y in arms A and B was 74.3% (95% CI: 56.4%-85.7%) and 83.3% (95% CI: 66.6%-92.1%). Overall response rates were 82.9% in arm A and 69.4% in arm B. During induction chemotherapy, 45.7% and 75.0% of patients in arms A and B, respectively, h …
Overall survival at 2 y in arms A and B was 74.3% (95% CI: 56.4%-85.7%) and 83.3% (95% CI: 66.6%-92.1%). Overall response rates were …
85 results